LEChENIE OSTEOPOROZA: VOPROSY EFFEKTIVNOSTI I BEZOPASNOSTI DENOSUMABA V REAL'NOY KLINIChESKOY PRAKTIKE
- Authors: Toroptsova N.V1, Nikitinskaya O.A1, Korotkova T.A1, Demin N.V1, Anikin S.G1
-
Affiliations:
- Issue: No 16 (2015)
- Pages: 77-80
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288238
- ID: 288238
Cite item
Open Access
Access granted
Abstract
The article presents results of the 12-month prospective study of women with postmenopausal osteoporosis treated by genetically engineered drug denosumab. A year later, there was a significant increase in bone mineral density of the lumbar spine, femoral neck and total hip index by 4.98%, 3.2 and 3.0%, respectively. That effect was not significantly dependent on whether before prescribing denosumab the patients were given other anti-osteoporotic medications. There were no fracture cases during the follow-up. Only 5% of patients refused to continue treatment after 6 months, which was not associated with the medication side effects.
Full Text
About the authors
N. V Toroptsova
Email: torop@irramn.ru
O. A Nikitinskaya
T. A Korotkova
N. V Demin
S. G Anikin
References
- Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003;423:337-42.
- Jang G., Peterson M. Denosumab, an inhibitor of RANKL, has pharmacokinetics similar to other monoclonal antibodies. J. Bone. Miner.Res. 2006;21(Suppl. 1):S190.
- McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., Peacock M., Miller P.D., Lederman S.N., Chesnut C.H., Lain D., Kivitz A.J., Holloway D.L., Zhang C., Peterson M.C., Bekker P.J.; for the AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density'. N. Engl. J. Med. 2006;354:821-31.
- Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B, Austin M., Liu Y., San Martin J.; for the Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43:222-29.
- Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., San Martin J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 2008;93: 2149-57.
- Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., Delmas P., Zoog H.B., Austin M., Wang A., Kutilek S., Adami S., Zanchetta J., Libanati C., Siddhanti S., Christiansen C.; for the FREEDOM Trial. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 2009;361:756-65.
- Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio L.H., Hadji P., Hofbauer L.C., Alvaro-Gracia J.M., Wang H., Austin M., Wagman R.B., Newmark R., Libanati C., San Martin J., Bone H.G. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J. Bone. Miner. Res. 2009;24:153-61.
- Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., Man H.S., San Martin J., Bone H.G. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy. J. Bone. Miner. Res. 2010;25(1):72-81.
- Silverman S.L., Gold D.T. Compliance and persistence with osteoporosis therapies. Curr. Rheumatol. Rep. 2008;10:118-22.
Supplementary files
